ChemT Biotechnology announced that it has raised US$5 million in total funding over the past 18 months. The total includes US$1 million in angel investment and a US$4 million seed round. The seed round was led by Wavemaker Ventures, the early-stage fund of Wavemaker Partners. SEEDS, an arm of SG Growth Capital, also participated.
Additional investors included Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator.
ChemT Biotechnology is an AI-driven biotechnology company building what it describes as the intelligence layer for biomanufacturing.
The company is focused on helping advanced medicines become easier to manufacture, scale, and deliver to patients worldwide.
ChemT said biomanufacturing remains constrained by long development timelines, unpredictable yields, high costs, and processes that are difficult to scale. The company is addressing these challenges by building intelligence directly into the manufacturing process to better understand and guide cell behavior.
At the center of ChemT’s platform is CelMo, an AI-driven Virtual Cell platform trained on proprietary biological sequencing data and validated in the lab.
CelMo is designed to simulate how cells respond to manufacturing conditions, genetic changes, and other stresses. The platform tracks biological processes such as growth, metabolism, stress response, and productivity to help identify cell pathways that can improve manufacturing performance.
ChemT said CelMo has demonstrated a 50% increase in antibody output and a 40% reduction in production timelines in CHO cells, which are commonly used to manufacture antibodies and therapeutic proteins.
The company’s flagship small molecule product, Chemplify, applies a similar approach to T-cell manufacturing for advanced cancer therapies. ChemT said Chemplify has demonstrated 50% faster development, 3x scalability, 60% lower costs, and 10x higher cell expansion yield.
The new funding will support the expansion of ChemT’s AI and experimental infrastructure, advancement of AI-designed molecular products toward GMP standards and regulatory readiness, scaling of commercial partnerships, and further development of CelMo.
ChemT also plans to expand the platform beyond CHO cells and T cells into other cellular systems, including stem cells, natural killer cells, and HEK cells.
The company said it has built commercial partnerships with more than 40 pharmaceutical, biotech, and CDMO companies globally within roughly a year and a half of launch.
ChemT Biotechnology is based across Singapore and the United States.
KEY QUOTES:
“This financing is a strong validation of our team, our technology, and our mission during a difficult funding environment for life sciences. Within roughly a year and half of launch, we’ve built commercial partnerships with more than 40 pharmaceutical, biotech, and CDMO companies across the globe. The future of biomanufacturing will not be won by automation alone — it will require intelligence.”
Jie Sun, Co-Founder and CEO of ChemT Biotechnology
“Our customers come to us because they are stuck – development timelines stretch for years, processes break when you try to scale them. CelMo is the cellular world model to understand what’s happening inside their cells and intervene intelligently. Our goal is to help make advanced medicines easier to manufacture, scale, and deliver to patients worldwide.”
Dr. Ling Wu, Co-Founder and President of ChemT Biotechnology
“Biomanufacturing has long been constrained by structural bottlenecks, rooted in the lack of computational understanding of how cellular networks behave inside bioreactors. ChemT addresses this through precision small molecules that modulate cellular behavior — giving manufacturers a new lever for faster, cheaper, and higher-yield production with consistent quality. We look forward to working with ChemT’s founding team, which brings together technical and commercial depth, scientific credibility, world-class bioprocess leadership, and capital efficiency — a rare combination that has already drawn early commercial partnerships from all over the world.”
Paul Santos, Co-Founder and Managing Partner of Wavemaker Partners
